ArticleRadiation oncology (London, England)2015
Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.
Article in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 160 citations in OpenAlex.
- Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial.Journal of the National Cancer Institute · 2025Trial
- A feasibility study on adaptiveStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Trial
- The impact of robustness of deformable image registration on contour propagation and dose accumulation for head and neck adaptive radiotherapy.Journal of applied clinical medical physics · 2018Trial
- Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.Radiation oncology (London, England) · 2015Trial
- Feasibility and potential benefits of daily online adaptive radiotherapy for head and neck cancer without margin reduction using an RTT-only workflow.Clinical and translational radiation oncology · 2027Article
- Dose monitoring-guided replanning timing in adaptive radiotherapy for laryngeal cancer.Physical and engineering sciences in medicine · 2026Article
- Evaluating synthetic CT from deformable registration in directed adaptive radiotherapy for head and neck cancer.Journal of applied clinical medical physics · 2026Article
- Daily adaptive radiotherapy in head and neck squamous cell carcinoma can negatively impact organ at risk dosimetry.Clinical and translational radiation oncology · 2026Article
- Estimation of accumulated dose to organs at risk in head and neck cancer patients treated with scheduled replanning and dose painting in the ARTFORCE trial.Physics and imaging in radiation oncology · 2026Article
- Automatic target volume segmentation for offline adaptive head-and-neck radiotherapy.Journal of applied clinical medical physics · 2026Article
- Evaluation of deformable image registration vs offline adaptive replanning in post-op oral cavity cancer treated with volumetric modulated Arc therapy.Scientific reports · 2026Article
- A subgroup analysis of locally advanced nasopharyngeal carcinoma patients with small lymph nodes and large nodes using adaptive radiotherapy.BMC cancer · 2025Article
- Investigating the necessity of adaptive radiotherapy in tomotherapy of head and neck cancer patients.Radiation oncology (London, England) · 2025Article
- Real-time morphological and dosimetric adaptation in nasopharyngeal carcinoma radiotherapy: insights from autosegmented fractional fan-beam CT.Radiation oncology (London, England) · 2025Article
- Radiotherapy toxicities: mechanisms, management, and future directions.Lancet (London, England) · 2025Review
- Adaptive radiotherapy in locally advanced head and neck cancer: The importance of reduced margins.Physics and imaging in radiation oncology · 2025Article
- Article
- An Observational Dosimetric Study in Definitively Treated Primary Head and Neck Cancers: To Assess the Effect of Weight Loss and Change in Lateral Neck Dimensions on the Difference Between Dose Planned and Received by the Parotid(s) and Correlation with Adaptive Radiation Therapy.Advances in radiation oncology · 2024Article
- Interdisciplinary Collaboration in Head and Neck Cancer Care: Optimizing Oral Health Management for Patients Undergoing Radiation Therapy.Current oncology (Toronto, Ont.) · 2024Review
- Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view.Cancer medicine · 2024Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge anatomical variations occur during the course of intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNC). The risks are therefore a parotid glands (PG) overdose and a xerostomia increase. The purposes of the study were to estimate: - the PG overdose and the xerostomia risk increase during a "standard" IMRT (IMRTstd); - the benefits of an adaptive IMRT (ART) with weekly replanning to spare the PGs and limit the risk of xerostomia. MATERIAL AND
methodsFifteen patients received radical IMRT (70 Gy) for LAHNC. Weekly CTs were used to estimate the dose distributions delivered during the treatment, corresponding either to the initial planning (IMRTstd) or to weekly replanning (ART). PGs dose were recalculated at the fraction, from the weekly CTs. PG cumulated doses were then estimated using deformable image registration. The following PG doses were compared: pre-treatment planned dose, per-treatment IMRTstd and ART. The corresponding estimated risks of xerostomia were also compared. Correlations between anatomical markers and dose differences were searched.
resultsCompared to the initial planning, a PG overdose was observed during IMRTstd for 59% of the PGs, with an average increase of 3.7 Gy (10.0 Gy maximum) for the mean dose, and of 8.2% (23.9% maximum) for the risk of xerostomia. Compared to the initial planning, weekly replanning reduced the PG mean dose for all the patients (p<0.05). In the overirradiated PG group, weekly replanning reduced the mean dose by 5.1 Gy (12.2 Gy maximum) and the absolute risk of xerostomia by 11% (p<0.01) (30% maximum). The PG overdose and the dosimetric benefit of replanning increased with the tumor shrinkage and the neck thickness reduction (p<0.001).
conclusionDuring the course of LAHNC IMRT, around 60% of the PGs are overdosed of 4 Gy. Weekly replanning decreased the PG mean dose by 5 Gy, and therefore by 11% the xerostomia risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.